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Introduction
The debilitating nature of chronic cluster headache (CH)
can negatively impact a patient’s quality of life (QoL). In
recent years, non-invasive neuromodulation devices have
been of increasing interest for the treatment of CH.
Aim
The Prevention and Acute Treatment of Chronic Clus-
ter Headache (PREVA) study was designed to evaluate
the clinical effects—including QoL outcomes—of gam-
maCore®, a non-invasive vagus nerve stimulation device
(nVNS), in subjects with chronic CH.
Methods
PREVA was a randomized, well-controlled study com-
prised of a 2-week run-in phase, a 4-week randomized
(1:1; nVNS vs standard of care [SoC]) phase, and a 4-week
extension phase. Subjects delivered stimulations prophy-
lactically twice daily (mandatory) or optionally for the res-
cue treatment of CH attacks. Three validated scales (EQ-
5D-3L™, Headache Impact Test™ [HIT-6], and Hospital
Anxiety and Depression Scale [HADS]) were used to
assess the QoL of subjects at the end of each study phase.
Results
A total of 97 subjects were randomized to treatment;
data from 93 subjects (n = 45 nVNS; n = 48 SoC) were
included in the efficacy analysis population. Compared
with subjects treated with SoC alone, subjects also trea-
ted with nVNS reported greater overall improvements
in EQ-5D-3L, HIT-6, and HADS scores from the end of
run-in to the end of the randomized phase. As of June
2014, QoL data from the extension phase were not
available; however, they will be available for presentation
at EHMTIC.
Conclusion
Compared with SoC, use of nVNS for the both preventive
and acute treatment of CH was associated with greater
improvement in QoL as assessed on 3 validated
instruments.
Abstract submitted on behalf of the PREVA Study
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